Finance

Lists
Why is CYTK down २.७१%?
Dive Deeper
CYTK:NASDAQ
Cytokinetics, Inc.
US$ ६३.८२
-२.७१%
(-१.७८) 1D
अक्टोबर ५, ११:५२:४७ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Open
US$ ६५.६०
High
US$ ६५.७६
Low
US$ ६३.२२
Mkt. cap
८.८७ अरब
Avg. vol.
२०.३० लाख
Volume
९.२५ लाख
52-wk high
US$ ८८.३१
52-wk low
US$ ५४.३०
EPS
-US$ ७.२२
Beta
०.४१
Shares outstanding
१३.९० करोड
No. of employees
६७३
Open
US$ ६५.६०
High
US$ ६५.७६
Low
US$ ६३.२२
Mkt. cap
८.८७ अरब
Avg. vol.
२०.३० लाख
Volume
९.२५ लाख
52-wk high
US$ ८८.३१
52-wk low
US$ ५४.३०
EPS
-US$ ७.२२
Beta
०.४१
Shares outstanding
१३.९० करोड
No. of employees
६७३
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
१८ घण्टा पहिले
Cytokinetics stock heads into four October heart presentations
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees६७३
Founded१९९७
HeadquartersSouth San Francisco, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to CYTK in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current US$ ६३.८२
US$ १४६.०० (+१२८.७५%)
Average
US$ ११०.२७ (+७२.७७%)
Lowest
US$ ८५.०० (+३३.१८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Serge Belanger
Needham
Buy
Maintained
US$ ११२.००
+७५.५%
10/05/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
US$ १०५.००
+६४.५%
10/02/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
US$ १४०.००
+११९.४%
09/30/2026
Leonid Timashev
RBC Capital
Buy
Maintained
US$ ११२.००
+७५.५%
09/10/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
US$ ११२.००
+७५.५%
09/01/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
US$ १००.००
+५६.७%
08/31/2026
Jason Zemansky
Bank of America Securities
Hold
Maintained
US$ ८५.००
+३३.२%
08/31/2026
Paul Choi
Goldman Sachs
Buy
Reiterated
US$ १०५.००
+६४.५%
08/28/2026
Emily Field
Barclays
Buy
Reiterated
US$ ११०.००
+७२.३%
08/26/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
-
-
08/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$ १०७.००
+६७.६%
08/07/2026
James Condulis
Stifel Nicolaus
Buy
Reiterated
US$ १०८.००
+६९.२%
08/07/2026
Jason Butler
Citizens JMP
Buy
Maintained
US$ ११०.००
+७२.३%
08/07/2026
Mayank Mamtani
B. Riley Securities
Buy
Reiterated
US$ १४६.००
+१२८.८%
07/31/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
US$ १०३.००
+६१.४%
07/23/2026
Eric Joseph
Citi
Buy
Maintained
US$ ९९.००
+५५.१%
07/16/2026
Ashwani Verma
UBS
Buy
Upgraded
US$ ११५.००
+८०.२%
06/29/2026
Salim Syed
Mizuho Securities
Buy
Maintained
US$ ११८.००
+८४.९%
06/23/2026
Unknown Analyst
Citi
Buy
Initiated
US$ ९९.००
+५५.१%
05/19/2026
Unknown Analyst
Raymond James
Hold
Maintained
-
-
05/06/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
-
-
02/25/2026
Last report
२०२६ अगस्ट ६
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ १.५० / -US$ १.६१
+६.५९%beat
Revenue / Est. (USD)
२.८६ करोड / १.८० करोड
+५९.४६%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१९.३६ लाख
१.७८ करोड
१.९४ करोड
२.८६ करोड
Cost of goods sold
९.९२ करोड
१०.४४ करोड
९.८१ करोड
१०.३४ करोड
Cost of revenue
९.९२ करोड
१०.४४ करोड
९.८१ करोड
१०.३४ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६.९५ करोड
९.१७ करोड
१०.४९ करोड
१०.४४ करोड
Operating expense
६.९५ करोड
९.१७ करोड
१०.४९ करोड
१०.४४ करोड
Total operating expenses
१६.८७ करोड
१९.६१ करोड
२०.३० करोड
२०.७८ करोड
Operating income
-१६.६८ करोड
-१७.८४ करोड
-१८.३६ करोड
-१७.९२ करोड
Other non operating income
-२१.०० लाख
१.४२ करोड
-१.०० लाख
१३.०० लाख
EBT including unusual items
-३०.६२ करोड
-१८.३० करोड
-२०.६० करोड
-१९.८८ करोड
EBT excluding unusual items
-१८.४९ करोड
-१८.३० करोड
-२०.६० करोड
-१९.८८ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-३०.६२ करोड
-१८.३० करोड
-२०.६० करोड
-१९.८८ करोड
Net profit margin
-१५,८१४.९८%
-१,०३०.८७%
-१,०६४.४८%
-६९४.३९%
Earnings per share
-१.५४
-१.५०
-१.६७
-१.५०
Interest and investment income
१.०२ करोड
१.१५ करोड
१.१० करोड
१.३९ करोड
Interest expense
-२.६३ करोड
-३.०३ करोड
-३.३३ करोड
-३.४८ करोड
Net interest expenses
-१.६१ करोड
-१.८९ करोड
-२.२३ करोड
-२.०९ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-१६.४१ करोड
-१७.५५ करोड
-१८.०२ करोड
-१७.५५ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू